BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36968998)

  • 41. Prognostic value of CEA and CA19-9 in patients with local advanced rectal cancer receiving neoadjuvant chemoradiotherapy, radical surgery and postoperative chemotherapy.
    Shan J; Gu B; Shi L; Wang X; Ye W; Zhou W; Sun X
    Transl Cancer Res; 2021 Jan; 10(1):88-98. PubMed ID: 35116242
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.
    Huang MY; Lee HH; Tsai HL; Huang CW; Yeh YS; Ma CJ; Huang CM; Chen CY; Huang JJ; Wang JY
    Radiat Oncol; 2018 Mar; 13(1):53. PubMed ID: 29587797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
    Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
    BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
    Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Nakao T; Kashihara H; Wada Y; Yoshimoto T; Okikawa S; Yamashita S; Shimada M
    BMC Cancer; 2022 Dec; 22(1):1263. PubMed ID: 36471264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of failure in patients with locally advanced rectal cancer receiving pre-operative or post-operative chemoradiotherapy.
    Yeo SG; Kim MJ; Kim DY; Chang HJ; Kim MJ; Baek JY; Kim SY; Kim TH; Park JW; Oh JH
    Radiat Oncol; 2013 May; 8():114. PubMed ID: 23647920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
    BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
    Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
    Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Poor prognostic and staging value of tumor deposit in locally advanced rectal cancer with neoadjuvant chemoradiotherapy.
    Wang Y; Zhang J; Zhou M; Yang L; Wan J; Shen L; Liang L; Yao Y; Zhang H; Zhang Z
    Cancer Med; 2019 Apr; 8(4):1508-1520. PubMed ID: 30790459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preoperative Chemoradiation in Locally Advanced Rectal Cancer: Efficacy and Safety.
    Peponi E; Skloupiotis V; Tsironis D; Tasiou I; Capizzello A; Tsironis C; Tsimoyiannis KE; Pitouli E; Tsimoyiannis E; Tsekeris P
    Gastroenterology Res; 2015 Dec; 8(6):303-308. PubMed ID: 27785313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term results of intraoperative presacral electron boost radiotherapy (IOERT) in combination with total mesorectal excision (TME) and chemoradiation in patients with locally advanced rectal cancer.
    Krempien R; Roeder F; Oertel S; Roebel M; Weitz J; Hensley FW; Timke C; Funk A; Bischof M; Zabel-Du Bois A; Niethammer AG; Eble MJ; Buchler MW; Treiber M; Debus J
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1143-51. PubMed ID: 16979835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy.
    Gaber G; El Achy S; Khedr GA; Parimi V; Helenowksi I; Donnelly ED; Strauss JB; Woloschak G; Wei JJ; Small W; Refaat T
    Am J Clin Oncol; 2021 Feb; 44(2):58-67. PubMed ID: 33284239
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Timing to achieve the best recurrence-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: experience in a large-volume center in China.
    Wang X; Zheng Z; Zhu H; Yu Q; Huang S; Lu X; Huang Y; Chi P
    Int J Colorectal Dis; 2021 May; 36(5):1007-1016. PubMed ID: 33398511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term Outcomes of Lower Rectal Cancer Patients Treated with Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection after Preoperative Radiotherapy or Chemoradiotherapy.
    Sakamoto W; Ohki S; Onozawa H; Okayama H; Endo H; Fujita S; Saito M; Saze Z; Momma T; Takenoshita S; Kono K
    J Anus Rectum Colon; 2021; 5(2):129-136. PubMed ID: 33937552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer.
    McCarthy K; Pearson K; Fulton R; Hewitt J
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008368. PubMed ID: 23235660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Five-year outcomes of preoperative chemoradiation for rectal carcinoma in Saudi population: single-institutional experience.
    AlSaeed EF; Tunio M; Zubaidi A; Al-Obaid O; Ahmed AK; Al-Omar OA; Abid EA; Alsiwat MJ
    Ann Saudi Med; 2015; 35(1):23-30. PubMed ID: 26142934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A good preoperative immune prognostic index is precits a better prognosis for locally advanced rectal cancer patients with ypTNM stage II who underwent radical resection after neoadjuvant chemoradiotherapy.
    Li S; Wang Y; Cai H; Pan Z; Guan G
    Int J Colorectal Dis; 2023 Jul; 38(1):184. PubMed ID: 37395868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer.
    Cheong C; Shin JS; Suh KW
    World J Gastroenterol; 2020 Nov; 26(44):7022-7035. PubMed ID: 33311947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.